A randomized phase II study of ixabepilone (BMS-247550) given daily × 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: An Eastern Cooperative Oncology Group study

Annals of Oncology

Volumn 19, Issue 5, 2008, Pages 977-983

  Burtness, Barbara A ^a   Manola, J ^b   Axelrod, R ^c   Argiris, A ^d   Forastiere, A A ^e  

^a FOX CHASE CANCER CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Antimicrotubule therapy; Epothilone; Squamous cell carcinoma of the head and neck

Indexed keywords

DOCETAXEL; IXABEPILONE; PACLITAXEL; TAXANE DERIVATIVE;

ADULT; AGED; ANOREXIA; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG RESPONSE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEAD AND NECK CANCER; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOMAGNESEMIA; HYPOTENSION; INCIDENCE; INFECTION; MAJOR CLINICAL STUDY; MALE; MELENA; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NEUTROPENIA; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SENSORY NEUROPATHY; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; STOMATITIS; THROMBOCYTE COUNT; TREATMENT DURATION;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; EPOTHILONES; FEMALE; HEAD AND NECK NEOPLASMS; HEMATOLOGIC DISEASES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PACLITAXEL; PERIPHERAL NERVOUS SYSTEM DISEASES; RECURRENCE; SALVAGE THERAPY; SURVIVAL ANALYSIS; TAXOIDS;

EID: 43049105410     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm591     Document Type: Article

References (21)

1. American Cancer Society. Cancer Facts and Figures 2007. http.//www.cancer.org/downloads/STT/CAFF2007PWSecured.pdf.
2. Forastiere AA, Metch B, Schuller DE et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: A Southwest Oncology Group study. J Clin Oncol 1992; 10: 1245-1251.
3. Forastiere AA, Leong T, Rowinsky E et al. Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393. J Clin Oncol 2001; 19: 1088-1095.
4. Gibson MK, Li Y, Murphy B et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): An intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2005; 23: 3562-3567.
5. Hanania EG, Fu S, Zu Z et al. Chemotherapy resistance to taxol in clonogenic progenitor cells following transduction of CD34 selected marrow and peripheral blood ceUs with a retrovirus that contains the MDR-1 chemotherapy resistance gene. Gene Ther 1995; 2: 285-294.
6. Schibler MJ, Huang B. The colR4 and colR15 beta-tubulin mutations in Chlamydomonas reinhardtii confer altered sensitivities to microtubule inhibitors and herbicides by enhancing microtubule stability. J Cell Biol 1991; 113: 605-614.
7. Bollag DM, McQueney PA, Zhu J et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 1995; 55: 2325-2333.
8. Lee FY, Borzilleri R, Fairchild CR et al. BMS-247550: A novel epithilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 2001; 7: 1429-1437.
9. Gadgeel SM, Wozniak A, Boinpally RR et al. Phase I clinical trial of BMS-247550, a derivative of epithilone B, using accelerated titration 2B design. Clin Cancer Res 2005; 11: 6233-6239.
10. Zhuang SH, Agrawal M, Edgerly M et al. A Phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days. Cancer 2005; 103: 1932-1938.
11. Abraham J, Agrawal M, Bakke S et al. Phase I trial and pharmacokinetic study of BMS-247550, an epathilone B analog, administered intravenously on a daily schedule for five days. J Clin Oncol 2003; 21: 1866-1873.
12. Dickson N, Peck R, Wu C, Burris H. Ixabepilone given weekly in patients with advanced malignancies: Final efficacy and safety results of a phase I trial. J Clin Oncol 2006; 24(18S): 2040.
13. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-16.
14. Atkinson EN, Brown BW, Confidence limits for probability of response in multistage phase II clinical trials. Biometrics 1985; 41: 741-744.
15. Mehta CR, Patel NR, Tsiatis AA. Exact significance testing for ordered categorical data. Biometrics 1994; 40: 819-825.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
17. Langer CJ, Li Y, Jennings T et al. Phase II evaluation of 96-hour paclitaxel infusion in advanced (recurrent or metastatic) squamous cell carcinoma of the head and neck (E3395): A trial of the Eastern Cooperative Oncology Group. Cancer Invest 2004; 22: 823-831.
18. Herbst RS, Arquette M, Shin DM et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23: 5578-5587.
19. Baselga J, Trigo JM, Bourhis J et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23: 5568-5577.
20. Burtness B, Goldwasser MA, Flood W et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 2005; 23: 8646-8654.
21. Lee JJ, Low JA, Croarkin E et al. Changes in neurologic function tests may predict neurotoxicity caused by ixabepilone. J Clin Oncol 2006; 24: 2084-2091.